Abstract: Provided is a monoclonal antibody or a fragment thereof in which heavy-chain complementarity-determining regions (CDRs) 1 to 3 respectively consist of amino acid sequences of SEQ ID NOs: 2 to 4 and light-chain CDRs 1 to 3 respectively consist of amino acid sequences of SEQ ID NOs: 5 to 7; a monoclonal antibody or a fragment thereof in which heavy-chain CDRs 1 to 3 respectively consist of amino acid sequences obtained by deleting, substituting, or adding one or several amino acids in the amino acid sequences of SEQ ID NOs: 2 to 4 and light-chain CDRs 1 to 3 respectively consist of amino acid sequences obtained by deleting, substituting, or adding one or several amino acids in the amino acid sequences of SEQ ID NOs: 5 to 7, and which has binding properties to a KK-LC-1 protein; or a monoclonal antibody or a fragment thereof which competes with the monoclonal antibody or a fragment thereof in which the heavy-chain CDRs 1 to 3 respectively consist of the amino acid sequences of SEQ ID NOs: 2 to 4 and the light-ch

Abstract: The present invention provides novel PGI2 derivatives and an anti Helicobacter agent, a platelet function potentiating agent or a cervical ripening agent containing any of the derivatives.

Abstract: An embossed carrier tape used for carrying electronic devices, includes a plurality of pockets in which the electronic devices are held. Each of the pockets includes a plurality of inner side surfaces which are separated by ridge lines. Each of the pockets is shaped so that corners of the electronic device are not in contact with the ridge lines thereof.

Abstract: An embossed carrier tape used for carrying electronic devices, includes a plurality of pockets (device holes) in which the electronic devices are held one by one. Each of the pockets (device holes) includes a plurality of inner side surfaces which are separated by ridge lines. Each of the pockets (device holes) is shaped so that corners of the electronic device are not in contact with the ridge lines thereof.

Abstract: The present invention relates to a process for separating 2,7-DMN, characterized in that a mixture containing at least 50% by weight of 2,7-DMN and the other DMN isomers obtained by preliminarily concentrating a fraction in the range of 250.degree.-270.degree. C. of catalytically cracked petroleum oil is preliminarily adjusted to a temperature of 60.degree.-90.degree. C. to form a slurry containing the crystal of 2,7-DMN, which is placed in a tightly sealed pressure vessel, adiabatically pressurized to the range of 500-2,500 kgf/cm.sup.2 and solidified to form a state of co-existing of solid and liquid phases, liquid is then discharged under pressure from the solid-liquid co-existing system, the solid remaining in the vessel is pressed to discharge the liquid remaining between the solid particles, which are integrated to give 2,7-DMN having a purity of 98% by weight or more.

Abstract: The invention intends to separating a methyl derivative of naphthalene (2,6-dimethyl naphthalene or 2-methyl naphthalene) from a mixture material in a high purity more than 98 weight %. The starting material is preliminarily treated at a raised temperature up to 220.degree. c. at the highest and with LHSV of 0.1-6 Hr.sup.-1 in the presence of an acid catalyst usually used for olefin polymerization. The treated material is distillated to remove the polymerized impurities and to raise the naphthalene derivative content at least up to 50 weight %. And then the obtained material is subjected to the crystallization under a pressure of 500-2500 kgf/cm.sup.2 at a temperature of 80.degree.-150.degree. C. (for 2,6-DMN) or 10.degree.-35.degree. C. (for 2-MN).